Relmada Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
No other changes.
No other changes.
Annual filing, covered
10-K parsed · Mar 19 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 19 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
Relmada Therapeutics, Inc.
4.22
−0.05 · −1.13%
post 4.22 −0.02%
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Relmada Therapeutics, Inc..
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Relmada Therapeutics, Inc..
| Manager | Value | % base | |
|---|---|---|---|
| Jupiter Topco | $77.3M | 11.12% | — |
| BlackRockindex-like | $51.4M | 7.39% | +475.92% |
| Squadron | $50.9M | 7.32% | −13.27% |
| VR Adviser | $47.4M | 6.81% | +41.31% |
| Spruce Street Capital | $44.2M | 6.36% | +2.06% |
| Manager | Value | % base | |
|---|---|---|---|
| Jupiter Topco | $77.3M | 11.12% | — |
| BlackRockindex-like | $51.4M | 7.39% | +475.92% |
| Squadron | $50.9M | 7.32% | −13.27% |
| VR Adviser | $47.4M | 6.81% | +41.31% |
| Spruce Street Capital | $44.2M | 6.36% | +2.06% |
Bull1
Bear2
Expected move
Inputsspot 4.17exp Nov 20ATM strike 5ATM straddle 0.95IV 62%